NCT07007325

Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis and Disease Progression

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Institut Cancerologie de l'Ouest · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

\[68Ga\]Ga-PentixaFor PET-CT will be performed in patients with Small cell lung cancer (SCLC) to confirm the targeting of CXCR4 by \[68Ga\]Ga-PentixaFor

Detailed description

Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, but remains a cancer with a poor prognosis, often detected at a metastatic stage and associated with a high rate of early recurrence. Therapeutic options for unresectable SCLC are limited and essentially rely on first-line radiochemotherapy for limited disease or chemo-immunotherapy, possibly supplemented by radiotherapy, for extensive disease. CXCR4 is a chemokine receptor that is highly expressed in this cancer. By targeting CXCR4 with \[177Lu\]Lu-PentixaTher or \[90Y\]Y-PentixaTher, patients with SCLC could benefit from a new type of treatment in this indication: Peptide Receptor Radionuclide Therapy (PRRT). However, there is a need for a preliminary diagnostic study due to a lack of published data. \[68Ga\]Ga-PentixaFor is an experimental compound that binds with high affinity to CXCR4 and appears to be a promising candidate for PET-CT imaging of SCLC. This initial step is crucial to confirm CXCR4 targeting by \[68Ga\]Ga-PentixaFor before considering PRRT with therapeutic radionuclides such as Lu-177 or Y-90 in future trials.

Conditions

• Small Cell Lung Carcinoma (SCLC)

Interventions

Type	Name	Description
DRUG	[68Ga]Ga-PentixaFor	\[68Ga\]Ga-PentixaFor PET-CT

Timeline

• Start date: 2025-09-15
• Primary completion: 2027-09-15
• Completion: 2029-09-15
• First posted: 2025-06-05
• Last updated: 2025-06-05

Locations

3 sites across 1 country: France